Letter

Turning a blind eye:Why we don't test for blindness at the end of our trials

BMJ 2004; 328 doi: 10.1136/bmj.328.7448.1136-a (Published 6 May 2004)
Cite this as: BMJ 2004;328:1136.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. David L Sackett, trialist (sackett@bmts.com)
  1. Trout Research and Education Centre at Irish Lake, RR 1, Markdale, ON, Canada N0C 1H0

    EDITOR—I write with reference to the paper by Fergusson et al.1 Asking patients or their clinicians at the end of a trial which drug they think they were taking confounds failures in blinding with successes in pre-trial hunches about efficacy.

    Thirty years ago, at the end of the first ever trial of aspirin and sulfinpyrazone …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular